SLC5A2 and obesity disorder: Additionally, sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists are recommended for treating obesity and its related complications due to their dual effects on weight loss and renoprotection [5].